Media  Kit

For Media Inquiries, please contact:

Christine Lindenboom
VP, Investor Relations & Corporate Communications
media@alnylam.com

 

Fact Sheets

  • Alnylam Corporate Overview (PDF)
  • RNA Interference (RNAi) and the Future of Drug Development (PDF)
  • Hereditary ATTR Amyloidosis (hATTR amyloidosis) Backgrounder (PDF)
  • APOLLO Phase 3 Clinical Trial Overview (PDF)

 

Photos

Executive Officers

 

Illustrations

 

Logos

SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.